These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15670547)

  • 41. Pharmacological interventions to manage coronary heart disease.
    Parkinson D
    Nurs Times; 2003 Jul 8-14; 99(27):48-9. PubMed ID: 12882058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
    Genest J; Pedersen TR
    Circulation; 2003 Apr; 107(15):2059-65. PubMed ID: 12707251
    [No Abstract]   [Full Text] [Related]  

  • 43. [Secondary prevention of coronary heart disease].
    von Schacky C
    MMW Fortschr Med; 2003 Mar; 145(13):28, 30, 32-3. PubMed ID: 15101529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The polypill in the primary prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Fundam Clin Pharmacol; 2010 Feb; 24(1):29-35. PubMed ID: 20002198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
    Sanz G; Fuster V; Guzmán L; Guglietta A; Arnáiz JA; Martínez F; Sarria A; Roncaglioni MC; Taubert K
    Am Heart J; 2011 Nov; 162(5):811-817.e1. PubMed ID: 22093195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
    Rastegarpanah M; Malekzadeh F; Thomas GN; Mohagheghi A; Cheng KK; Marshall T
    Arch Iran Med; 2008 May; 11(3):306-13. PubMed ID: 18426322
    [No Abstract]   [Full Text] [Related]  

  • 47. [Secondary prevention after myocardial infarct].
    Trenkwalder P; Lydtin H
    Dtsch Med Wochenschr; 1990 Oct; 115(40):1519-27. PubMed ID: 1976501
    [No Abstract]   [Full Text] [Related]  

  • 48. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
    Kaski JC; Fernandez-Berges D
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Recommendations for secondary prevention after myocardial infarction].
    Arntz HR
    Z Kardiol; 2004; 93 Suppl 1():I23-5. PubMed ID: 15022004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of arteriosclerosis.
    Schmermund A; Erbel R
    Dtsch Med Wochenschr; 2003 Jan; 128(1-2):41-7. PubMed ID: 12510249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Secondary prevention of cardiovascular diseases].
    Schneider CA; Erdmann E
    Internist (Berl); 2004 Jun; 45 Suppl 1():S23-30. PubMed ID: 15148584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. President's page: the promise of prevention: so, why aren't all cardiologists "preventive"?
    Wolk MJ; Bairey Merz CN; Thompson PD
    J Am Coll Cardiol; 2004 Nov; 44(10):2082-4. PubMed ID: 15542296
    [No Abstract]   [Full Text] [Related]  

  • 53. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Canadian Hypertension Education Program. Brief overview of 2004 recommendations.
    Campbell N;
    Can Fam Physician; 2004 Oct; 50():1411-5. PubMed ID: 15526879
    [No Abstract]   [Full Text] [Related]  

  • 55. National guidelines for the management of absolute cardiovascular disease risk.
    Usherwood T
    Med J Aust; 2013 Aug; 199(4):243-4. PubMed ID: 23984778
    [No Abstract]   [Full Text] [Related]  

  • 56. [Prevention of cardiovascular and degenerative diseases: II. Hormones and/or Mediterranean diet].
    Martin-Du Pan R
    Rev Med Suisse Romande; 2003 Mar; 123(3):183-9. PubMed ID: 15095705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Letter by Alter and Rupp regarding article, "OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction".
    Alter P; Rupp H
    Circulation; 2011 Jul; 124(1):e23; author reply e24-5. PubMed ID: 21730314
    [No Abstract]   [Full Text] [Related]  

  • 58. Fixed dose combination therapy and CVD protection: "a need of the hour".
    Chopra HK
    Indian Heart J; 2009; 61(4):316-21. PubMed ID: 20635732
    [No Abstract]   [Full Text] [Related]  

  • 59. [The polypill as cardiovascular prophylactic: clinical trials].
    Sandli OK; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polypill in cardiovascular disease: has it's time come?
    Kuppuswamy V; Choo WK; Gupta S
    Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.